Coffee Consumption and Liver Disease Pathophysiology

Coffee is increasingly recognised for its protective effects against a spectrum of liver disorders, notably non-alcoholic fatty liver disease and its inflammatory sequel, non-alcoholic steatohepatitis. The bioactive components of coffee, including caffeine and chlorogenic acids, exhibit antioxidant, anti-inflammatory and antifibrotic properties. These compounds modulate hepatocyte metabolism by attenuating oxidative stress, regulating lipid droplet biogenesis and inhibiting pathways that drive cell death under lipotoxic conditions. At the fibrotic stage, coffee constituents appear to suppress activation of hepatic stellate cells, thereby limiting extracellular matrix deposition. Epidemiological evidence links higher coffee intake with reduced prevalence of steatosis, lower degrees of fibrosis and improved markers of liver function. Mechanistic studies further implicate inhibition of pro-inflammatory signalling cascades and modulation of the gut–liver axis, suggesting that coffee consumption may influence hepatic immunity and barrier integrity. This convergence of clinical observation and laboratory research underscores the global significance of coffee as a readily accessible intervention to mitigate the burden of liver disease.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Coffee Consumption and Liver Disease Pathophysiology publication trend

The graph below shows the total number of articles in coffee consumption and liver disease pathophysiology across all publications each year (not limited to Nature Index journals).

Technical terms

Non-alcoholic fatty liver disease (NAFLD): A condition characterised by excess fat accumulation in liver cells not caused by alcohol intake.

Non-alcoholic steatohepatitis (NASH): An advanced form of NAFLD featuring inflammation, hepatocyte injury and varying degrees of fibrosis.

Hepatic stellate cells: Resident liver cells that, when activated by injury or inflammation, transform into collagen-producing myofibroblasts and drive fibrosis.

NLRP3 inflammasome: A multiprotein complex in immune cells that, upon activation, triggers maturation of pro-inflammatory cytokines and can exacerbate liver injury.

Lipotoxicity: Cellular damage resulting from accumulation of toxic lipid species within hepatocytes, leading to oxidative stress and cell death.

References

1. Coffee Compounds Protection Against Lipotoxicity Is Associated with Lipid Droplet Formation and Antioxidant Response in Primary Rat Hepatocytes. Antioxidants (2025).
2. Beverage consumption in patients with metabolic syndrome and its association with non-alcoholic fatty liver disease: a cross-sectional study. Frontiers in Nutrition (2024).
3. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients (2023).
4. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology (2011).
5. Caffeine Inhibits the Activation of Hepatic Stellate Cells Induced by Acetaldehyde via Adenosine A2A Receptor Mediated by the cAMP/PKA/SRC/ERK1/2/P38 MAPK Signal Pathway. PLOS ONE (2014).
6. Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut–liver axis. Journal of Nutritional Science (2019).
7. Coffee Intake and Liver Steatosis: A Population Study in a Mediterranean Area. Nutrients (2018).
8. Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. Nutrients (2017).
9. Caffeine Inhibits NLRP3 Inflammasome Activation by Downregulating TLR4/MAPK/NF-κB Signaling Pathway in an Experimental NASH Model. International Journal of Molecular Sciences (2022).